Abiomed (ABMD)

This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below.

From 1

Company Information:

Company Address:

22 Cherry Hill Drive

Danvers, MA 01923

Company’s Web Address: http://www.abiomed.com

Industry Sector:

Fiscal Year:

Dividend:


Note: this section is not editable. Please click here to report any inaccuracies.
Shares Outstanding: 26,800,000
Market Capitalization: Updating...

Income Statements
Click for: Annual Income Statement
Click for: Quarterly Income Statement

Balance Sheets
Click for: Annual Balance Sheet
Click for: Quarterly Balance Sheet

Cash Flow Statements
Click for: Annual Cash Flow Statement
Click for: Quarterly Cash Flow Statement

SEC Filings
Click for: Form 10-Ks
Click for: Form 10-Qs
Click for: Annual Proxy Statements
Link to SEC filings search: http://www.sec.gov/cgi-bin/srch-edgar

Company Overview:

Note: this section is not editable.

Headquartered in Danvers, Massachusetts and founded in 1981, Abiomed Inc. (ABMD) is engaged in developing, manufacturing and marketing of medical products designed to assist or replace the pumping function of the failing heart. The company's strategy focuses on heart recovery as the goal for all acute cardiac attacks. Abiomed's products are designed to enable the heart to rest, heal and recover. The company's products can be used in a range of clinical settings, including by heart surgeons for patients in profound cardiogenic shock. Profound cardiogenic shock is starvation of the cells, or not enough blood flow to the organs as a result of an imbalance between oxygen supply and oxygen demand. Shock is a result of a weakened heart that is unable to pump blood as efficiently as it once did. Shock commonly occurs after a heart attack. The company's products can also be used by interventional cardiologists for patients who are in pre-shock or in need of prophylactic support in the cardiac catheterization lab (cath lab). The company has designed three FDA-approved products for heart recovery following acute events: the BVS 5000 biventricular support system (BVS), the AB5000 circulatory support system (AB5000) and the iPulse Circulatory Support System. There are two primary types of devices used in the cath lab and surgery suite for circulatory support for pre-shock and profound shock patients: intra-aortic balloons (IABs), an inflatable balloon inserted by a catheter that is used as an initial line of therapy in the cath lab or the surgery suite for patients with diminished heart function, and ventricular assist devices (VADs) that are mechanical devices which helps in the pumping function of the failing heart. The iPulse multi-purpose console supports the IAB, and also supports the AB5000 and BVS 5000 systems. The company also developed the AbioCor Implantable Replacement Heart for severe biventricular heart failure when chronic patients are ineligible for a heart transplant. In Europe, Abiomed offers the minimally invasive Impella Circulatory Support System.

Read full report on Abiomed, Inc. Company overview provided by Abiomed, Inc. Overview

Company Products/Services/Markets:

Enter Company Products/Services Here

Strategy:

Describe Key Aspects of Company's Strategy Here

Competitors:

Enter Competitors Here

Industry Trends and News:

Enter Industry Trends and News Here

Acquisitions, Divestitures, Major Transactions, Spin-offs :

Enter Acquisitions, Divestiures, Major Transactions, Spin-offs Here

Management – Pros & Cons, Changes:

Enter Management - Pros & Cons, Changes Here

Financial Analysis:

Enter Financial Analysis Here

Valuation:

Enter Valuation Analysis and Valuation Ratios Here

  2007 2006 2005
Price/Earnings


Price/EBITDA


Price/Pre-tax Income


Price/Revenue


Investment Rationale:

Buy Rationale:

Enter Buy Rationale Here

Sell Rationale:

Enter Sell Rationale Here

Projected Financials:

Income Statement: (Paste Here)

Balance Sheet: (Paste Here)

Cash Flow Statement: (Paste Here)

Financial Ratios: (Paste Here)

Other: (Paste Here)

Discussion:

This area is for debates regarding different recommendations for this stock.

Footnotes:

News:

Yahoo! Finance Blog
Getting the most out of the Interactive Chart
If you’ve clicked the thumbnail chart — or a time period link below it — on our quote page, you’ve likely visited our Interactive Chart. The Interactive Chart is a relatively new addition to Yahoo! Finance; it became generally available in April. There are several things you can do on the Interactive Chart that you [...]
Real-Time ECN Quotes Are Now Available on Multi-Quote and Portfolios Pages!
Thanks to everyone for the great feedback on our recent real-time features on Yahoo! Finance. We know this is information you value, so today we’re pleased to build on our real-time features with the addition of Real-Time ECN views in multi-quote and portfolio pages on Yahoo! Finance. With the markets being volatile and earnings right around [...]
Comprehensive Coverage on Commodities Futures on Yahoo! Finance
Yahoo! Finance is the industry leader for providing up-to-date information on companies, including free real-time quotes. Did you know that we also provide comprehensive coverage on commodities? Go to http://finance.yahoo.com/futures to discover what’s happening with commodities. With energy prices soaring, energy futures provide insight into where the market thinks energy prices are headed. Precious metals (for [...]
Yahoo! Finance Launched more Real-Time ECN Features Today!
Today we are delighted to announce more Real-Time ECN information. We have created a new page that has real-time streaming prices for the bid, bid size, ask, ask size and the top of the book. The top of the book is commonly referred to as Level 2 data and this features the 5 highest bid prices [...]
Yahoo! Finance Launches Free Real-Time ECN Prices
We are very excited to announce the availability of free US real-time ECN quotes on Yahoo! Finance. Many of you will remember this was a very popular feature that Yahoo! Finance provided through August 2006 when due to consolidation in the marketplace and a new pricing structure it was removed. We’ve been listening to your feedback [...]

See Also (links to blogs, forums, external sources, etc...):

Tags:
none
The opinions and views expressed in this document do not necessarily reflect the views or opinions of InvestingMinds. InvestingMinds did not prepare and does not endorse such content. Please note that it is intended for general circulation only and the recommendations contained herein do not take into account the specific investment objectives, financial situation or particular needs of any particular person. This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy securities or other instruments. No part of this document may be reproduced in any manner without the written permission of InvestingMinds.
 
Images (0)
 
Comments (0)
You must login to post a comment.